The Institutional Biosafety Committee (IBC) is responsible for the review and oversight of research involving biological agents conducted at or on behalf of Northwell Health. The IBC ensures that research involving these agents is conducted in a manner that protects researchers, laboratory personnel, human research subjects, the public and the environment ensuring compliance with the NIH Guidelines federal and state regulations, and institutional policies.
Research involving biological agents requires:
- Registration and review by a health system authorized IBC and is conducted in accordance with determinations of the IBC; environmental, health and safety requirements; and other applicable requirements;
- Review by an Institutional Review Entity (IRE) for select agents if covered under the U.S. Government Policy for Dual Use Research of Concern (DURC);
- Training for all individuals involved in the conduct of the research, including those involved in the handling and management of biological agents.
What Type of Biological Agents or Toxins Require Review by the IBC?
- Recombinant and synthetic nucleic acid molecules
- Microorganisms (infectious agents, bacteria, viruses, protozoans, fungi, etc.);
- Biologically Derived Toxins;
- Human and/or non-human primate blood, body fluids, cells or tissue culture, surgical biopsy, established cell lines, etc.);
- Transgenic animals, invertebrates, and/or plants;
- Artificial Gene Transfer;
- Select Agents;
- Dual Use Research of Concern (DURC);
- Synthetic Biology; or
- Wild animals or wild animal tissue
How Do I Submit to the IBC?
The health system has two authorized IBCs registered with the National Institutes of Health (NIH) Office of Biotechnology Activities (OBA). Use of any IBC other than the following is not permitted.
Feinstein Institute Pre-Clinical IBC – Northwell Health: reviews basic science and pre-clinical research using biological agents conducted at or on behalf of the health system. Also functions as the Institutional Review Entity (IRE) for research considered Dual Use Research of Concern (DURC).
Feinstein Institute Clinical IBC – Northwell Health: reviews clinical research using biological agents conducted at or on behalf of the health system. Also functions as the Institutional Review Entity (IRE) for research considered Dual Use Research of Concern (DURC).
- IBC Registration Form
- Administrative Request Form
- Northwell Health IBC Policies and Procedures
- Northwell Health IBC Roster
|IBC Submission Deadline||Northwell Health IBC Meetings|
|July 25, 2016
August 29, 2016
September 26, 2016
October 24, 2016
November 21, 2016
|July 11, 2016
August 8, 2016
September 12, 2016
October 10, 2016
November 7, 2016
December 5, 2016
For questions regarding the Northwell Health IBC, please contact:
Michelle Aparicio, BS, CPIA
Director, IACUC & IBC
IBC General Email: firstname.lastname@example.org
How Do I Take the Required Training?
All individuals involved in research using biological agents must receive the appropriate level based on the type of research involved and should include those involved in the handling and management of biological agents. To satisfy regulatory training you may go to CITI Program at citiprogram.org.
Go to “My Learner Tools” for Northwell Health and select “Add a Course or Update Learner Groups”. Select the appropriate type of research you will be conducting and the required courses will pre-populate in your course profile.
For more information on accessing the CITI Program, click here.